January 23, 2024 News by Andrea Lobo, PhD FDA grants fast track status to KYV-101 for progressive forms of MS The U.S. Food and Drug Administration (FDA) has granted fast track status to KYV-101, Kyverna Therapeuticsā cell-based therapy candidate for people with progressive forms of multiple sclerosis (MS) that are treatment-resistant. The FDA designation is intended to accelerate the development of therapies that aim to address unmet medical…
March 27, 2023 News by Marisa Wexler, MS More, earlier damage seen in primary progressive MS vs SPMS People with primary progressive multiple sclerosis (MS) may experience more severe inflammatory activity and nerve damage early on in the course of their disease as compared with individuals who have secondary progressive MS, a new study indicates. The results also suggest that primary progressive MS patients tend to have…
January 18, 2023 News by Marisa Wexler, MS FSD Asking to Open Trial of Lucid-MS, Myelin-protecting Therapy FSD Pharma has submitted an application to Health Canada asking to start a Phase 1 clinical trial of Lucid-MS, the company’s experimental and myelin-protective oral therapy for people withĀ multiple sclerosis (MS). The trial will not involve patients and is designed to investigate the safety and tolerability of…
January 3, 2023 News by Lindsey Shapiro, PhD FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3 clinical trial of its investigational treatment masitinibĀ in people with progressive forms of multiple sclerosis (MS). The decision follows approvals in several European countries that will also host trial sites, including…
October 20, 2022 News by Patricia Valerio, PhD Infections Nearly 4 Times as Likely for Patients With Progressive MS People with progressive forms of multiple sclerosis (MS) are nearly four times more likely to have serious infections ā those leading to hospitalization ā than those with relapsing-remitting MS (RRMS), according to a large study in Germany. This higher infection risk was found despite the fact that, during…
October 1, 2021 News by Patricia Inacio, PhD CALLIPER Trial for Progressive MS Enrolls First Patient Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the companyās two identically-designed Phase 3 trials, dubbed…
January 22, 2021 News by Marta Figueiredo, PhD SERPINA3 Nerve Injury-induced Protein May Be Biomarker of PPMS People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…